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Cardiomyocyte relaxation and contraction are tightly controlled by the activity of the cardiac sarco(endo)plasmic reticulum (SR) Ca2+ transport
ATPase (SERCA2a). The SR Ca2+-uptake activity not only determines the speed of Ca2+ removal during relaxation, but also the SR Ca2+ content
and therefore the amount of Ca2+ released for cardiomyocyte contraction. The Ca2+ affinity is the major determinant of the pump's activity in the
physiological Ca2+ concentration range. In the heart, the affinity of the pump for Ca2+ needs to be controlled between narrow borders, since an
imbalanced affinity may evoke hypertrophic cardiomyopathy. Several small proteins (phospholamban, sarcolipin) adjust the Ca2+ affinity of the
pump to the physiological needs of the cardiomyocyte. It is generally accepted that a chronically reduced Ca2+ affinity of the pump contributes to
depressed SR Ca2+ handling in heart failure. Moreover, a persistently lower Ca2+ affinity is sufficient to impair cardiomyocyte SR Ca2+ handling
and contractility inducing dilated cardiomyopathy in mice and humans. Conversely, the expression of SERCA2a, a pump with a lower Ca2+
affinity than the housekeeping isoform SERCA2b, is crucial to maintain normal cardiac function and growth. Novel findings demonstrated that a
chronically increased Ca2+ affinity also may trigger cardiac hypertrophy in mice and humans. In addition, recent studies suggest that some models
of heart failure are marked by a higher affinity of the pump for Ca2+, and hence by improved cardiomyocyte relaxation and contraction. Depressed
cardiomyocyte SR Ca2+ uptake activity may therefore not be a universal hallmark of heart failure.
© 2006 Elsevier B.V. All rights reserved.Keywords: SR Ca2+ATPase; Phospholamban; Sarcolipin; Cardiac hypertrophy; Heart failure; SERCA2a1. Introduction
In eukaryotic cells, cytosolic calcium (Ca2+) represents an
almost universal second messenger controlling a multitude of
cell functions, amongst which cardiac muscle contraction was
one of the first to be recognized [1,2]. How a second messenger
that cannot be formed nor destroyed, but can only be shifted
from one location to another, has acquired the ability to
independently and simultaneously control so many cellular
activities remains incompletely understood. This short overview
focuses on the role of the SERCA2 Ca2+-transport ATPases
which help to shape the complex spatio-temporal subcellular
Ca2+ patterns in the cardiomyocyte.
Cardiomyocyte depolarization triggers Ca2+ entry into the
cell via depolarization-activated L-type Ca2+ channels. Ca2+
that enters the cell binds to and opens specialized Ca2+-release⁎ Corresponding author. Tel.: +32 16330213; fax: +32 16345991.
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doi:10.1016/j.bbamcr.2006.08.025channels (ryanodine receptor type 2 or RYR2) in the nearby
sarcoplasmic reticulum (SR), inducing the release of a much
larger quantity of Ca2+ from this intracellular Ca2+ store. The
concomitant transient rise in cytosolic Ca2+ leads to binding of
Ca2+ to troponin C (TnC) allowing the thin (actin) and thick
(myosin) filaments to interact and develop force [3]. For
relaxation to occur, Ca2+ must be removed from the cytosol to
dissociate Ca2+ from TnC. At least three processes coordinate
this removal of Ca2+: (i) the SR Ca2+ ATP-ase type 2a
(SERCA2a) which pumps Ca2+ back into the SR using the
hydrolysis of ATP as a source of energy, (ii) the Na+/Ca2+
exchanger (NCX) which uses the energy of the Na+ and Ca2+
gradients across the plasma membrane to exchange 3
extracellular Na+ ions for 1 intracellular Ca2+ ion and (iii) the
plasma-membrane Ca2+ ATPase (PMCA), which extrudes Ca2+
from the cell using the energy liberated by ATP hydrolysis [3].
In general, Ca2+ re-uptake into the SR is quantitatively more
important than Ca2+ removal to the external medium. However,
this relative importance varies between species [4]. In rabbit and
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the rest is extruded from the cell by NCX (28%) and PMCA
(2%). Rodents cycle 90% of Ca2+ through the SR and only 10%
via the extracellular space [3,5]. As Ca2+ release from the SR is
the major source of Ca2+, the amount of Ca2+ available for
release and thus the SR Ca2+ content controls cardiac
contractility. Therefore, Ca2+ uptake into the SR via SERCA2a
is a major determinant of both cardiac relaxation and
contraction [6].
Given this central role of SERCA2a in cardiac function, it
is not surprising that alterations in its Ca2+ affinity strongly
affect cardiac function. As will be discussed in this review,
controlling the affinity of the pump for Ca2+ is not only
crucial for normal cardiac contractile control, but it is also
important for the regulation of cardiomyocyte growth.
Modulators of the Ca2+ affinity are therefore essential tools
to adjust the Ca2+ affinity of the pump to the physiological
needs of the cardiomyocyte. Moreover, the choice of a
SERCA isoform with a proper affinity for Ca2+ is of great
physiological importance.
2. Cardiac splice variants of SERCA2 show differences in
Ca2+ affinity
Cardiac muscle exploits splice variant SERCA2a, which
presents a lower affinity for Ca2+ compared to the house-
keeping SERCA2b, to control cellular Ca2+ movements [7].
The SERCA2a isoform is identical to SERCA2b except for its
carboxyl terminus (Fig. 1A). The four COOH-terminal amino
acids of SERCA2a are replaced by an extended hydrophobic
sequence of 49 amino acids in SERCA2b, comprising an
eleventh transmembrane and a short luminal segment.
Consequently, the extreme C-termini of SERCA2a and
SERCA2b are situated at opposite sides of the ER membrane
(with the SERCA2b tail protruding into the lumen) [7].
Studies mainly using the COS or HEK-293 cell expression
systems showed that the extended tail of SERCA2b alters the
functional properties of the pump. These in vitro studies
revealed that SERCA2b shows a two-fold higher affinity for
Ca2+ and two-fold lower catalytic turnover rate for Ca2+
uptake and ATP hydrolysis. [8–11]. Recent studies on the
isoform properties in vivo confirmed the higher Ca2+ affinity
of SERCA2b compared to SERCA2a, but differences in the
maximal pumping rate were not observed [12,13]. The
isoforms share the same sensitivity to phospholamban (the
endogenous SERCA2 regulator) and to thapsigargin (a
specific inhibitor of the SERCA pumps) [9].
It is remarkable that a number of post-mitotic cells that
make heavily use of Ca2+ signaling rely on SERCA2a to
control either contraction (as in cardiac-, slow-twitch skeletal
and differentiated contractile smooth muscle) [14] or neuro-
transmitter release (as in some, mostly GABAergic neurons)
[15]. While each of these cell types also express (usually
lower levels of [16]) SERCA2b for house-keeping functions,
the majority of the transcripts of the ATP2A2 gene in these
cells are alternatively processed to generate a SERCA2a-
encoding mRNA [17]. The alternative transcript processingthat leads to the production of SERCA2a mRNAs involves
choices that have to be made concerning the use of two
alternative splice donor sites and two polyadenylation sites
[18]. How exactly this process is controlled in these muscles
and neuronal cells remains largely unexplored, but a detailed
study of the 3′ end of the ATP2A2 gene described the minimal
cis-acting structural requirements of the ATP2A2 transcript
needed to allow regulated processing [18]. Clearly, the
activation of an otherwise inefficient splicing mechanism is
part of the differentiation pathway of muscle and neuronal
cells and this is responsible for the switch from SERCA2b
expression in undifferentiated cells to expression of SERCA2a
in the differentiated state [18]. It is noteworthy that
invertebrates (Caenorhabditis, Artemia), which, in contrast
to vertebrates, do not have three but only a single SERCA
gene, already show the expression of two different spliced
SERCA isoforms that structurally and functionally correspond
to the vertebrate SERCA2a and SERCA2b isozymes [19] [20].
The duality of the SERCA(2) isoforms is therefore an
evolutionary old feature. In this review, we will focus on the
SERCA2 isoforms and will not address the SERCA3 splice
variants. All SERCA3 isoforms are characterized by a low
(supra micromolar) Ca2+ affinity and are not expressed in
myocardial cells [8,21].
3. Modulators of the Ca2+ affinity: phospholamban and
sarcolipin
The need for an accurate regulation of SERCA2's Ca2+
affinity is underscored by the existence of two membrane-
inserted regulator proteins phospholamban (PLB) and sarcolipin
(SLN) (Fig. 1). The only known physiological function of these
small proteins is to act in essence as Ca2+-affinity modulators of
SERCA2a, SERCA2b or occasionally of the skeletal-muscle
variant SERCA1a. Note that the low-Ca2+-affinity pump
SERCA3 appears to be insensitive to these modulators.
3.1. Molecular properties and function of PLB
The main regulator of SERCA2a is PLB, a small
transmembrane protein (52 amino acids) present in the
ventricles and to a lower extent in the atria of the heart [22].
PLB monomers interact with SERCA2a and reversibly inhibit
the Ca2+-transport activity of the pump. PLB also forms
homopentamers, which are considered as an inactive pool of
PLB (Fig. 1B) [23]. The principal effect of the association of
PLB with SERCA2a is to lower the apparent affinity of
SERCA2a for Ca2+, with little or no effect on the maximal
pumping rate at saturating Ca2+ and ATP concentrations [24,25]
(although a stimulatory effect on the maximal pumping activity
has been suggested [26,27]).
The inhibition of the pump by PLB is reversible. At non-
resting Ca2+ concentrations, the binding of Ca2+ to the pump
promotes the dissociation of the PLB/SERCA2a complex [28].
Also phosphorylation of PLB relieves the functional inhibition
of SERCA by PLB and increases the pump's affinity for Ca2+
(Fig. 1B) [28], without changing the maximal pumping rate
Fig. 1. A physiological window for the Ca2+ affinity of the SERCA2 pump. From left to right, modulations which gradually reduce the Ca2+ affinity of the SERCA2
pump. In the heart, the Ca2+ affinity needs to be critically controlled to remain in the physiological window of the Ca2+ affinity in order to ensure proper cardiac
function. Perturbations which lead to excessive (extreme left) or depressed (extreme right) Ca2+ affinity induce cardiac hypertrophic remodeling. See main text for
more details. (A) The cardiac-specific SERCA2a (b) and the house-keeping SERCA2b (a) isoforms differ in their carboxyl-terminus. The extra 49 amino acid tail of
SERCA2b protrudes in the SR membrane and is responsible for the higher affinity of the pump for Ca2+. An excessive affinity of the pump for Ca2+ in the heart may
trigger cardiomyopathy (a). (B) PLB forms an equilibrium between the monomeric (inhibitory, b) and pentameric (inactive pool, a) state. PLB monomers inhibit
SERCA2a by direct interaction (c). This functional inhibition is reversed by phosphorylation (d) by protein kinase A (PKA) or Ca2+-calmodulin kinase II (CaMKII).
(e) Superinhibition of the pump (e.g. by more PLB monomers, stronger PLB–SERCA2 interaction, defective phosphorylation) leads to chronically depressed
cardiomyocyte contractility and cardiac hypertrophy and heart failure. (C) SLN monomers (a) interact with SERCA2a resulting in inhibition of the pump (b). Putative
phosphorylation of SLN by serine/threonine 16 kinase (STK16) may be important in the regulation of SLN function, e.g. during β-adrenergic stimulation. (D)
Superinhibition by PLB–SLN heterodimers. SLN disrupts PLB pentamers by direct interaction with PLB (a). SLN–PLB heterodimers bind with high affinity to
SERCA2a (b). Superinhibition by SLN/PLB may trigger cardiac hypertrophy (b).
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its inhibitory properties and is controlled by the relative activity
levels of different kinases and phosphatases. PLB is phosphory-
lated by cAMP-dependent protein kinase A (PKA) at Ser16 and
by Ca2+-calmodulin dependent protein kinase II (CaMKII) at
Thr17 [29,30]. The major phosphatase responsible for dephos-
phorylation of PLB is protein phosphatase type 1 (PP1, 70%)
whereas protein phosphatase type 2A (PP2A) and type 2C
(PP2C) together account for about 20% of the phosphate
removal [31].3.2. Physiological role of PLB in cardiac function
Given the central position of SERCA2a in determining
cardiac relaxation and contraction, it is not surprising that the
phosphorylation-dependent regulation of SERCA2a by PLB
controls cardiac performance [32]. PLB is considered as a
physiological brake of the heart and is an important constituent
of the β-adrenergic cascade. β-adrenergic activation triggers
cAMP- and Ca2+-dependent phosphorylation of PLB which
reverses the inhibition of SERCA2a. Consequently, the
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and increases SR Ca2+ content and release. Together, strong
stimulatory effects on cardiac relaxation (lusitropic effects) and
contractility (inotropic effects) are observed (reviewed in [32]).
The expression level of PLB critically determines cardiac
relaxation and contraction in a gene-dosage-dependent manner.
Loss of PLB was associated with an increased Ca2+ affinity of
SERCA2a, which promoted cardiac SR Ca2+ uptake, content
and release, resulting in a hyperdynamic state of the heart [25].
Similar observations were done in the heart of heterozygous
PLB+/− mice, although the effect of reduced PLB levels on
cardiomyocyte and cardiac relaxation and contraction is smaller
than in homozygous PLB−/− [33].
The associated hyperdynamic state of the heart is well
tolerated in mice, without pathological consequences [34] or
reducing the exercise capacity [35]. Conversely, transgenic
overexpression of PLB in the murine heart reduced the apparent
Ca2+ affinity of SERCA2a, resulting in diminished cardiomyo-
cyte relaxation and contractility at baseline [36,37]. Stimulation
with β-agonists could reverse the increased inhibition of
SERCA2a via phosphorylation of PLB [36]. Interestingly,
transgenic mice overexpressing PLB at four-fold normal levels
displayed a spontaneous compensatory rise in (nor)adrenaline
levels in the blood which enhanced phosphorylation of PLB
[37]. In the long term, this compensatory response became
maladaptive, resulting in heart failure (HF), a syndrome in
which progressive deterioration of cardiomyocyte contractility
and cardiac pump function leads to an insufficient blood supply
in the body.
Chronic inhibition of the cardiac SR Ca2+ ATPase was also
observed upon overexpression of gain-of-function PLB mutants
in the heart [36–40]. These mutants greatly reduce the affinity
of the pump for Ca2+, decreasing cardiomyocyte Ca2+ kinetics
and mechanics. When the inhibition by PLB can be reversed by
endogenous β-agonists, life is not threatened, although
significant left-ventricular hypertrophy was detected [36,38].
However, heart failure may develop upon chronic inhibition of
SERCA2a, i.e. if the strong inhibition is not reversible by
endogenous β-agonists [37,39,40] (Fig. 1B).
Many studies addressed the physiological relevance of the
dual-site phosphorylation of PLB (more extensively reviewed
in [41]). During β-adrenergic stimulation, Ser16 is the dominant
phosphorylation site and a full β-effect can be mediated by
single-site phosphorylation at Ser16 [42]. Phosphorylation at
Thr17 may only occur after a sufficient rise in cytosolic Ca2+,
i.e. at the highest levels of β-adrenergic stimulation [41,43,44].
Both phosphorylations then contribute to the total PLB
phosphorylation and have additive effects on cardiomyocyte
relaxation [45]. Besides a role in the β-adrenergic response of
the heart, a number of studies indicated that CaMKII-dependent
phosphorylation of PLB at Thr17 may play an important role in
the frequency-dependent acceleration of cardiac relaxation
(FDAR) [46,47]. The rate of cardiac relaxation increases with
frequency, which is a fundamental physiological modulator of
myocardial performance. FDAR is thought to be mediated by
CaMKII [48], which is supported by the unique behavior of
CaMKII, acting as a frequency decoder by increasing its activitywith the frequency of Ca2+ spikes [49]. However, phosphory-
lation of PLB may not be the only target of CaMKII in this
process [50,51].
3.3. Molecular properties and function of SLN
Recent findings shed new light on the putative physiological
role of SLN, a homologue of PLB, in the heart (Fig. 1C) [52].
Like PLB, SLN interacts with and inhibits the SR Ca2+ ATPase
by lowering its apparent Ca2+ affinity without pronounced
effects on the maximal pumping rate [53,54]. SLN has a
transmembrane sequence similar to that of PLB, but differs at its
C and N termini. It lacks the regulatory cytosolic domain
(comprising Ser16 and Thr17 in PLB) and has a small luminal
domain that is entirely absent in PLB, which is important for
targeting SLN to the SR membrane [55] and anchoring SLN to
the SERCA pump [55,56].
A remarkable synergistic inhibitory effect was observed
when SLN and PLB were co-expressed with SERCA2a or
SERCA1a in HEK-293 cells (Fig. 1D) [53]. SLN has a higher
affinity for PLB monomers than PLB monomers have for other
PLB monomers. Therefore, and because SLN only has a weak
ability to form SLN oligomers [57], SLN can convert inactive
PLB pentamers into a larger number of active inhibitory
species, i.e. PLB monomers and PLB–SLN dimers. Modeling
studies illustrate that not only PLB or SLN alone can fit into the
hydrophobic PLB/SLN binding site of SERCA, but that a PLB–
SLN heterodimer would fit even tighter, exerting a stronger
inhibitory effect by blocking the conformational changes of the
Ca2+ pump [56]. Immunoprecipitation experiments confirmed
the formation of the stable ternary PLB–SLN–SERCA complex
[53,54,58]. These studies of the PLB–SLN complex hint at
another level of regulating the Ca2+ affinity of the SR Ca2+
ATPase.
3.4. Physiological role of SLN in cardiac function
Several observations point to a possible physiological role of
SLN in the heart. First, based on overexpression in HEK-293
cells, SLN has the ability to interact not only with SERCA1a but
also with SERCA2a affecting their Ca2+ affinity to a similar
extent [53]. Second, several observations now indicate that SLN
expression may be prominent in the heart [59]. Previously, SLN
was considered to be the regulator of SERCA1a and hence the
fast skeletal muscle counterpart of the SERCA2a inhibitor PLB
in the heart. However, in humans, SLN mRNA is also found in
the heart [52]. SLN in mouse and rat is abundantly expressed at
the mRNA and protein level in the atria of the heart (but is
absent in the ventricles) and is found to a lower extent in skeletal
muscle [58,60,61]. The superinhibitory effect of the PLB/SLN
complex on SR Ca2+ uptake activity may therefore be
prominent in the atria of the heart, where both regulators are
endogenously found [61].
SLN-mediated superinhibition in the atria appears counter-
intuitive and in apparent contradiction with the fact that the
atrial rate of Ca2+ removal is faster than that of the ventricles, an
effect that previously was ascribed to the higher SERCA levels
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SLN might however be important to fine-tune the β-adrenergic
response in the atria. This idea is corroborated by recent reports
describing a regulatory effect of β-stimulation mediated by
SLN [63,64]. In addition, the atrium and ventricle respond
differently to β-adrenergic stimulation. Koss et al. [22] and
Freestone et al. [65] both reported a smaller β-effect on atrial
than on ventricular relaxation, and attributed this to the lower
PLB content in the atria. However, in some conditions a
stronger [66] or more sensitive β-adrenergic effect was
observed in atria compared to ventricle [22]. This might require
the relief of combined SLN/PLB inhibition on SERCA, whereas
the relief of PLB inhibition alone would be insufficient.
The absence of SLN protein in the normal ventricle [61] does
not exclude developmental or disease related SLN expression in
this chamber. To better define the role of SLN in cardiac
physiology, adenoviral or transgenic overexpression of SLN
was studied in ventricular cardiomyocytes. When SLN is
introduced in ventricular cardiomyocytes, it appears to be
targeted to the same SR subcompartments as PLB [58] where it
has the ability to form a stable SLN/PLB/SERCA2a ternary
complex [54,58]. Two independent reports describe how
cardiac-specific overexpression of SLN in mouse reduced the
affinity of SERCA2a for Ca2+ [54,63]. In these studies on SLN
transgenes, a slowed cardiomyocyte relaxation and impaired
cardiac function was reported. The studies showed however
some discrepancies, which may depend on the SLN species
used for overexpression (rabbit versus mouse SLN, which may
slightly differ in their ability to inhibit SERCA activity). In one
of the SLN transgenes, the impaired SR Ca2+ ATPase activity
and cardiomyocyte contractility evoked a hypertrophic response
[54] (Fig. 1D). Depending on the report, at least three
mechanisms were held responsible for the reduced cardiac
contractility in SLN transgenic mice: (i) direct inhibition of
SERCA2a by SLN [54,63]; (ii) formation of the highly
inhibitory SLN/PLB binary complex [54,63] and (iii) a
reduction in PLB phosphorylation [54].
Importantly, the β-adrenergic agonist isoproterenol largely
restored contractility in SLN transgenes, suggesting that like it
is the case for PLB, also SLN inhibition can be reversed by β-
receptor activation [54,63]. The de-inhibition of SLN may be a
direct action of β-receptor stimulation on SLN, but an enhanced
phosphorylation of PLB by PKA in the presence of SLN cannot
be excluded [54]. However, the observation that β-agonist
stimulation still largely reversed the inhibitory effect of SLN on
Ca2+ dynamics in transgenic mice expressing SLN but lacking
PLB points to a direct effect on SLN [64].
How the inhibition of the SERCA pump by SLN(/PLB)
might be regulated in vivo remains unknown. Compared to
PLB, the cytosolic regulatory domain of SLN is much smaller,
with Ser4 and Thr5 (only Thr5 in human SLN) as putative
phosphorylation sites [64,67]. Attempts to phosphorylate SLN
by PKA, CaMKII or endogenous kinases in vitro were
unsuccessful and mutation of these sites had little or no effect
on the regulatory behavior of SLN on SERCA activity in HEK-
293 cells [67]. Nevertheless, serine/threonine 16 kinase could
bind to and reverse the inhibitory effect of SLN on SERCA1aactivity, an effect which is dependent on Thr5 [64]. Therefore,
these data suggest that β-adrenergic stimulation of the heart
might directly stimulate phosphorylation of SLN involving
serine/threonine 16 kinase. The physiological role of serine/
threonine 16 kinase in the regulation of SLN remains to be
addressed. But it is clear that many questions on the role of this
relatively novel SERCA2a regulator in the heart still need to be
answered.
4. A reduced Ca2+ affinity of SERCA2a in heart failure
4.1. SERCA2a activity is reduced in heart failure
End-stage heart failure is marked with depressed systolic
performance and diastolic dysfunction. The impaired contrac-
tility of the failing heart is at least partially reflected by a
decrease in the intracellular Ca2+ transient and a diminished SR
Ca2+ load. Diastolic dysfunction is associated with a prolonged
duration of the Ca2+ transient and elevated resting cytosolic Ca2+
concentration [68–71]. Reduced Ca2+ transport by SERCA2
likely contributes to the altered Ca2+ handling. In human heart
failure, most findings now indicate that the levels of SERCA2a
protein often decrease [70,72–77].
Although reduced SERCA2a expression seems to be a
hallmark of heart failure, a direct correlation between a reduced
SERCA2a activity and the development of heart failure does not
always hold. A number of loss-of-function mutations in the
human SERCA2 gene (ATP2A2) result in Darier's disease, an
autosomal dominantly inherited skin disorder [11,78,79].
Contrary to expectation, adult Darier disease patients display
normal cardiac performance and do not develop hypertrophic
cardiomyopathy or heart failure [80,81]. Neither domice lacking
one functional Atp2a2 allele (SERCA2+/−) develop cardiac
disease, although the SERCA2a content and its maximal
pumping rate were reduced by ∼35% in the heart [82].
Interestingly, the apparent Ca2+ affinity of the pump remained
unaltered in the heterozygote mice, which can be explained by
the spontaneous reduction in the inhibitory properties of PLB
(reduced expression, increased phosphorylation). This compen-
sation might, among others (like the increased NCX activity),
help to prevent hypertrophic remodelling [83].
Besides the reduced expression of SERCA2a, most studies
indicate that the levels of PLB protein remain unchanged in heart
failure patients [72–74]. The resulting increase in the PLB to
SERCA2a ratio would thus lead to a lower Ca2+ affinity of the
pump, which would add up with the lower pump level in causing
a prolonged cardiomyocyte relaxation time. In some patients a
reduced phosphorylation status of PLB at Ser16 and Thr17 was
also observed, further enhancing the inhibition by PLB [77,84].
The reduced phosphorylation status of PLB may partially be
explained by the downregulation of β-adrenergic receptors in
heart failure patients leading to a reduced activity of PKA. It
should be noted that impaired PKA activity may also indirectly
lower PLB phosphorylation via inactivation of inhibitor-1
(through reduced phosphorylation at Thr35). This, in turn,
reinforces the activity of PP1, the main phosphatase of PLB [85–
87]. Dephosphorylation, and thus inactivation of inhibitor-1may
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lin-dependent phosphatase which plays a pivotal role in the
hypertrophic response [89]. In addition, the Ca2+-dependent
protein kinase Cα may contribute to enhanced PP1 activity.
PKCα has the ability to phosphorylate inhibitor-1 at another site
(Ser67) than PKA, thereby depressing inhibitor-1 activity and
reinforcing PP1 [90].
The effects of a reduced SR Ca2+ uptake on the SR Ca2+
content in heart failure would be exacerbated by a leaky Ca2+
release channel in the SR (hyperphosphorylation of RyR2
would increase its open probability) [91] and an increase in
NCX activity in the plasma membrane [71]. Hyperphosphory-
lation of RyR2 contrasts strikingly with the reduced phosphory-
lation of PLB, but may depend on a local rise in cAMP levels,
associated with a reduced activity of the phosphodiesterase 4D
(PDE4D), which is anchored to RyR2 [92]. These observations
underscore that local changes in the activity of kinases and
phosphatases play an important role in the altered Ca2+
homeostasis in heart failure.
4.2. Detrimental effects of a low Ca2+ affinity: studies in
humans
Studies in transgenic mice overexpressing normal PLB [37]
or gain-of-function PLB mutants [39,40] suggested a causal
relationship between a chronically reduced Ca2+ affinity of the
Ca2+ pump, defective SR Ca2+ cycling and cardiac remodeling
leading to heart failure. This hypothesis was also tested in
humans by searching for gain-of-function mutations in the PLB
gene which could be associated with familial dilated cardio-
myopathy (Fig. 1B).
Two such types of PLB mutations have so far been
described: the Arg9Cys and Arg14Del mutants were linked to
familial dilated cardiomyopathy and both displayed a
dominant inheritance pattern [93,94]. The clinical findings
of these mutations were supported by studies in transgenic
mouse models of the mutants. Cardiac overexpression of the
Arg9Cys mutant caused a chronically reduced phosphoryla-
tion status of PLB, lowering SERCA2a's Ca2+ affinity,
cardiomyocyte Ca2+ handling and cardiac function. The lower
degree of PLB phosphorylation is due to an impaired PKA
effect. The Arg9Cys PLB mutant displays an enhanced
affinity for PKA resulting in a stabilized PLB–PKA complex.
The trapped PKA fails to phosphorylate not only the mutated
PLB but also the wild-type PLB molecules, explaining the
dominant effect of the mutation [93]. The strong super-
inhibitory effect of the Arg14Del mutant on the Ca2+ affinity
of the SR Ca2+ ATPase is likely related to the altered
structure of the mutant. Increased pentameric instability was
observed and β-stimulation failed to completely reverse the
inhibitory properties [94].
Another mutation in the upstream non-coding region of the
PLB gene (A to G at −77 bp) was found in one patient with
cardiac hypertrophy. This mutation increased PLB promoter
activity by 1.5-fold in neonatal rat myocytes, suggesting that it
may lead to depressed SR Ca2+ cycling and cardiac hypertrophy
in vivo [95].In conclusion, in line with observations in mice, the reported
long-term effects of increased PLB inhibition on the Ca2+
transient in human ventricular cardiomyocytes appear to be
sufficient to induce cardiac hypertrophy. Dilated cardiomyop-
athy in humans can develop when endogenous β-agonists no
longer can reverse inhibition of SERCA2a by PLB [93,94].
4.3. Therapeutic approaches aimed to improve the activity of
SERCA
Given the central role of reduced SR Ca2+ uptake, targeting
the SERCA2a–PLB interplay may have an important thera-
peutic potential. Hence, strategies were explored aimed to
increase the expression of the SR Ca2+ ATPase or to attenuate
its inhibition by PLB [96].
4.3.1. Increasing the expression of SERCA
Initial studies provided the proof of concept that increasing
the expression and activity of the SR Ca2+ pump enhanced
cardiomyocyte contractility [97,98]. In addition, cardiac-
specific transgenic overexpression of SERCA2a or of the
skeletal-muscle-specific SERCA1a isoform was associated with
increases in SR Ca2+ uptake, content and release, improving
cardiac relaxation and contractility [99–103]. Interestingly,
SERCA overexpression enhanced the maximal SR Ca2+ uptake
activity in the heart without changing the apparent affinity for
Ca2+ [100,101]. PLB expression remained unaffected, suggest-
ing that the inhibitory properties of PLB should be stronger to
keep the Ca2+ affinity of the SERCA2 uptake unchanged (e.g.
reduced PLB phosphorylation or an increased number of PLB
monomers).
The group of Hajjar further explored whether gene-transfer
of the SR Ca2+ ATPase would improve contractility in diseased
cardiomyocytes. SERCA2a gene delivery restored the per-
turbed Ca2+ handling and contractility in human failing
cardiomyocytes [104]. In vivo adenoviral gene transfer of
SERCA2a in aortic-banded rats also improved SR Ca2+ uptake
and cardiac function in transition to heart failure [105,106].
Systolic and diastolic parameters were restored to normal levels
with beneficial effects on survival, and without compromising
cardiac energetics [106]. Finally, depressed Ca2+ uptake and
cardiac relaxation in rats with diabetic cardiomyopathy were
also partially restored by transgenic overexpression of SER-
CA2a [107].
In general, gene-transfer of SERCA2 looks promising to
treat heart failure. However, increasing the number of Ca2+
pumps is not without danger. First, transgenic SERCA2a
overexpression increased the risk of acute arrhythmias and
sudden death in rats challenged with myocardial infarction
[108]. The associated increase in SR Ca2+ content might
promote SR Ca2+ leakage from the SR and trigger delayed
afterdepolarizations [108]. Second, excessive overexpression of
SR Ca2+ pumps fails to improve cardiomyocyte function and
decreases myocyte shortening. In these conditions, the
excessive Ca2+ uptake activity might result in a maximal SR
Ca2+ load so that more SERCA cannot further increase SR Ca2+
content. The high number of Ca2+ pumps might then compete
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contraction. Together, these observations warn to carefully
control the transfection efficiency of SERCA [109].
4.3.2. Enhancing the Ca2+ affinity of the pump
Interference with PLB function could be useful to enhance
the apparent affinity of the pump for Ca2+ and improve
cardiomyocyte function. Attenuation of PLB activity can be
achieved in several ways: knock-out of the PLB gene [25],
expression of antisense RNA of PLB [110], gene-delivery of
dominant-negative PLB mutants [111], gene-delivery of a
SERCA2 pump which is insensitive to PLB inhibition [112] and
gene-transfer of a PLB-targeted antibody [113].
Attenuation of PLB activity increased the rate of the decay of
the Ca2+ transient in isolated normal cardiomyocytes
[5,110,114,115]. More importantly, interference with PLB
inhibition restored the contractile parameters in isolated failing
cardiomyocytes [111,114–116] and could reverse cardiomyo-
cyte hypertrophy [114]. The beneficial effects of these
interventions were further confirmed in vivo in animal models
of hypertrophy and heart failure. Genetic ablation of PLB
prevented the onset of heart failure in MLP−/− mice [117] and
reversed depressed function and hypertrophic growth in
cardiomyocytes of calsequestrin-overexpressing hearts [118].
Cardiac hypertrophy was also attenuated in transgenic mice
with cardiac-specific overexpression of a SERCA2a mutant
deficient in the binding of PLB [112]. In addition, cardiac-
specific adenoviral gene-delivery of a pseudophosphorylated
PLB mutant (Ser16Glu) in hamsters or rat attenuated the
progression of heart failure, showing that PLB inhibition also
proved therapeutically efficacious after the onset of cardiomy-
opathy [119,120]. These studies support that targeting of PLB
activity may be therapeutically beneficial. Future studies are
needed to translate these findings into larger animal models.
5. A high Ca2+ affinity of SERCA and hypertrophic
cardiomyopathy
The notion that a reduced SR Ca2+ load is at the basis of the
reduced cardiac contractility in the failing heart has become
widely accepted. However, as is often the case in biology, the
story is more complex than initially thought. More recent
findings suggest that cardiac hypertrophy and heart failure may
be induced by chronic activation of the SR Ca2+ pump. In
addition, some heart failure models exhibit improved rather than
impaired baseline SR Ca2+ handling or are refractory to enhance
SR Ca2+ uptake.
5.1. Not all models of cardiac hypertrophy benefit from
targeting PLB
The studies discussed in Section 4 paint the uniform picture
that augmentation of cardiomyocyte contractility through
intervention with the SERCA2–PLB interaction is of significant
benefit to the failing myocardium. However, in several other
mouse models of hypertrophic cardiomyopathy and heart
failure PLB gene disruption provided no benefit [121–123].Importantly, PLB ablation in at least some of these models
could supernormalize cardiomyocyte Ca2+ cycling and con-
tractility, but a concomitant rescue in whole-organ performance
or hypertrophy was not observed [122,123]. In fact, the
persistent hypertrophy, together with altered chamber geometry
and defective intercellular communication, may prevent that
improved cardiomyocyte function is translated to the whole
heart [123].
Cardiac hypertrophy and heart failure are heterogeneous
disorders with diverse etiologies. Defects in Ca2+ handling may
therefore not represent a universal pathway in heart failure,
which points to the requirement of alternative therapeutic
interventions.
5.2. Detrimental effects of an excessive Ca2+ affinity of
SERCA2
5.2.1. Studies in mice
Given the beneficial effects of an increased Ca2+ affinity of
the SR Ca2+ ATPase on cardiac growth and function, it is rather
surprising that in the heart a SERCA2 isoform is expressed with
a lower affinity for Ca2+ (SERCA2a) than in most other cell
types (SERCA2b). The expression of SERCA2a is nevertheless
essential for normal cardiac development and function [12].
This is clearly shown by studies on SERCA2b/b mice in which
the SERCA2a isoform is replaced by the higher Ca2+-affinity
variant SERCA2b. As explained before, the primary transcripts
of the wild-type Atp2a2 allele can, depending on the cell-type
and differentiation status, be alternatively processed to
SERCA2b or SERCA2a. The full substitution of the SERCA2a
isoform by SERCA2b could therefore be obtained by prevent-
ing the alternative splicing of the SERCA2a pre-mRNA through
modification of the Atp2a2 gene [12]. The b/b superscript
indicates that both Atp2a2 alleles lack some gene sequences
necessary to allow SERCA2a specific splicing and hence can
only express the SERCA2b protein [12].
SERCA2b/b mice displayed a higher incidence of embryonic
and neonatal mortality, associated with structural cardiac
malformations (early phenotype). Adult SERCA2b/b animals
develop concentric left ventricular cardiac hypertrophy with
moderate cardiac dysfunction. [12]. However, the interpretation
of the SERCA2b/b phenotype was complicated by its apparently
compensatory expression of two-fold lower SERCA2 levels
compared to the SERCA2a protein levels in wild-type hearts
and by the stronger inhibitory properties of PLB (i.e. increased
PLB expression, reduced PLB phosphorylation) [12,13,124].
Importantly, PLB modulates the affinity of SERCA2a and
SERCA2b to the same extent [9]. Thus, the increased PLB/
SERCA2 ratio in SERCA2b/b mice could in principle contribute
to the impaired cardiac phenotype. Still, in contrast to other
models of increased PLB inhibition [37], the affinity-modulator
PLB plays a protective role in the heart of SERCA2b/b mice by
partially reducing the higher affinity of SERCA2b [13].
Ablation of PLB in the SERCA2b background further increased
the Ca2+ affinity of the pump, but with devastating effects on
cardiac function and survival (Fig. 1A). The uncompensated
higher Ca2+ affinity of SERCA2 in the latter mice aggravated
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restrictions. Moreover, PLB ablation severely reduced the
cardiac reserve which is associated with stress-induced acute
heart failure and death in these mice [13].
The question remains whether the lower SERCA2 levels in
these SERCA2b mice would contribute to the severe cardiac
phenotype. Interestingly, SERCA2b activity only becomes
limiting at high Ca2+ loads [124]. Moreover, ablation of PLB
in the SERCA2b background improved SR Ca2+ handling and
relaxation of the cardiomyocytes compared to wild-type,
despite a 3-fold reduction in the number of Ca2+ pumps [13].
Together, these observations indicate that due to the enhanced
Ca2+ affinity of SERCA2b SR Ca2+ uptake activity is not
limited. The reduced SERCA2 content in SERCA2b/b mice may
rather serve the same purpose as the enhanced PLB inhibition,
i.e. restrain the activity of the pump in the submicromolar Ca2+
concentration range in the cardiomyocyte [13].
In conclusion, protective mechanisms can be recruited that
limit the Ca2+ affinity of the SERCA2 pump. These compensa-
tions take place even if, as a result of the lower SERCA2 levels,
it entails a reduced maximal pumping rate at high cytosolic Ca2+
levels. Preventing excessive cytosolic Ca2+ removal by
SERCA2b in the low Ca2+ concentration range seems more
crucial to avoid excessive cardiac growth/hypertrophy than
maintaining a normal maximal pumping capacity [13].
5.2.2. Studies in humans
Interestingly, the findings in SERCA2b mice which in
addition also lack PLB, mirror the cardiac consequences of an
early-stop mutation in the PLB gene (Leu-39-stop) in human
patients with familial dilated cardiomyopathy [125]. In the
heterozygous state, the accompanying loss of functional PLB in
humans is associated with cardiac hypertrophy, but normal
contractile performance. Moreover, individuals homozygous
for this mutation develop dilated cardiomyopathy at a young
age. The apparent pathological effects caused by the absence of
PLB in human hearts contrast strikingly with the benefits
observed upon the loss of PLB in mice [125]. It should be taken
into account that due to the human-specific substitution in PLB
of Asn27 to Lys, PLB exhibits stronger inhibitory properties in
human than in other species [126]. This more prominent
inhibition by PLB may explain the different impact of PLB
deficiency on the heart in man versus mouse. Other fundamental
differences between man and mouse in the relative contribution
of Ca2+ cycled via the SR versus Ca2+ cycling through the
extracellular medium may also contribute to the species-
dependent effect of PLB ablation [125]. Importantly, the studies
of SERCA2b mice demonstrate that PLB deficiency in mice can
be as devastating as in humans, but only in the context of a pre-
established higher Ca2+ affinity of the SR Ca2+ -ATPase [13].
In conclusion, previous reports highlighted that a chronically
reduced Ca2+ affinity of the pump impairs cardiac function and
may lead to cardiac remodeling (Fig. 1B, D). In contrast, SR
Ca2+ pumps with a too high Ca2+ affinity may have equally
detrimental effects (Fig. 1A). The Ca2+ affinity of the pump
should therefore be tightly controlled and kept in a narrow
physiological window (Fig 1).5.3. High Ca2+ affinity, a reduced reserve and heart failure
One widely used mouse model of dilated hypertrophic
cardiomyopathy harbors a deficiency in a cytoskeletal protein,
the muscle-specific LIM protein (MLP) [127]. At odds with
reports on reduced PLB phosphorylation in human heart failure,
this model of heart failure is characterized by hyperpho-
sphorylation of PLB and a concomitant higher affinity of the
pump for Ca2+, resulting in faster cytosolic Ca2+ removal in the
cardiomyocyte [128,129]. Hyperphosphorylation of PLB was
also suggested to occur in two rat models of cardiac
hypertrophy, but these studies did not report a detailed analysis
of Ca2+ handling [130,131]. Furthermore, an increased
phosphorylation status of PLB was observed in a rabbit
model of heart failure, although at the same time overall
SERCA activity was reduced [132].
Importantly, the enhanced basal SR Ca2+-uptake activity in
the MLP−/− cardiomyocytes could not be further elevated at
higher stimulation frequencies indicating a reduced frequency-
dependent increase of Ca2+-release. This diminished reserve
might be a hallmark for the development of heart failure in the
MLP−/− mice [128]. Interestingly, similar to MLP−/− mice, the
cardiomyocytes of the SERCA2b/b mice lacking PLB also
displayed faster SR Ca2+ removal and high SR Ca2+ content at
baseline [13]. Preliminary results support the view that the SR
Ca2+ content could not be further enhanced by high frequency
stimulation, similar to the frequency response observed in the
MLP−/− cardiomyocytes. This was also associated with a
reduced orthosympathic cardiac reserve in vivo [13] which is
likely responsible for the stress intolerance and high mortality of
the SERCA2b mice. In humans, a reduced cardiac reserve has
been associated with increased morbidity and mortality [133],
suggesting that the lack of cardiac reserve in the SERCA2b
model might be a risk factor for the acute heart failure in stress
conditions [13].
Together, the findings in two non-related mouse models
suggest that a reduced reserve for frequency-dependent increase
of Ca2+ might represent a novel paradigm for altered Ca2+
handling in heart failure, underscoring the complexity of Ca2+
handling in the normal and failing heart.
5.4. Concluding remarks
In conclusion, the heart exploits several tools which
tightly control and adjust the affinity of the pump for Ca2+
within a narrow, physiological range. An imbalanced activity
of the SR Ca2+ pump by profound and long-term changes in
its Ca2+ affinity has a severe impact on cardiac growth and
function. Both a chronically reduced and increased Ca2+
affinity can evoke hypertrophic cardiomyopathy in mice and
humans. Heart failure is marked by a reduced affinity of
SERCA2a for Ca2+ which partially underlies the diastolic
dysfunction. However, this may not represent a universal
hallmark, since recent findings demonstrated that cardiac
hypertrophy and heart failure can be associated with a higher
Ca2+ affinity of the pump and consequently with improved
cardiomyocyte function.
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contraction, only little is known about how Ca2+ may drive
the vast number of Ca2+-dependent growth signals in the
heart. Some models propose that IP3-regulated Ca2+ pools
could more specifically target the growth/survival branch
[134]. Moreover, it is currently unclear how changes in the
activity of SERCA2a affect the Ca2+ movements that drive
cardiac contractility separately from those controlling growth
(hypertrophy) and cell survival. Many studies described the
beneficial effects of improving SERCA2 activity on cardiac
contractility and cardiac remodeling. However, in certain
settings attenuation of cardiac hypertrophy and better cardiac
function appear to be incompatible phenomena. Together,
these observations point to the complex interactions between
cardiac contractility and signaling, which are both under the
direct control of Ca2+.
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